Wall Street has overreacted to near-term headwinds for these two market leaders, creating a rare buying opportunity for long-term investors
Wall Street’s unrelenting obsession with high-flying, hype-driven tech concept stocks has left a handful of profitable, market-leading growth companies trading at deeply discounted valuations, as investors price in worst-case scenarios for temporary headwinds and ignore durable long-term fundamentals. For buy-and-hold investors tired of chasing overvalued, unprofitable names vulnerable to sharp pullbacks on missed earnings, two beaten-down stocks stand out for their rock-solid business models, resilient growth trajectories, and unprecedented margin of safety: Novo Nordisk (NVO) and PDD Holdings (PDD).
Over the past 12 months, shares of Danish pharmaceutical giant Novo Nordisk have cratered 36%, a steep pullback driven by two core market fears: intensifying competition in the red-hot GLP-1 weight loss and diabetes drug space, and worries the firm is falling behind archrival Eli Lilly in the race for category leadership. A recent CEO transition has only added to the sentiment overhang, with multiple short-term headwinds compressing the stock’s valuation to multi-year lows.
But the market’s panic has created a dramatic overshoot, with investors writing off a business whose core fundamentals remain fully intact. Novo Nordisk maintains consistent, industry-leading profitability, boasting a hefty 33% operating margin, while its blockbuster Ozempic and Wegovy franchises hold dominant global market share. Late last year, the firm secured FDA approval for its oral weight loss treatment, expanding its product portfolio and unlocking new growth avenues beyond injectable therapies.
While management has guided for a temporary revenue decline in 2026, that near-term blip does not erase the massive, underpenetrated global GLP-1 market, which is still in the early innings of its long-term growth cycle. Backed by a deep clinical pipeline, decades of metabolic disease expertise, and unmatched brand loyalty among patients and providers, Novo Nordisk’s long-term competitive moat remains unbroken.
Most notably, the stock trades at a forward P/E ratio of just 13, based on consensus analyst estimates — a steep discount to its 10-year historical average, its large-cap pharma peers, and the S&P 500’s broader forward multiple. For long-term investors, that valuation offers a rare low-risk entry point into a category-defining business, with a wide buffer against further near-term volatility.
PDD Holdings, the parent company of fast-growing global e-commerce platform Temu, has also been swept up in Wall Street’s short-sighted pessimism. Shares are down 12% over the past 12 months, and more than 30% off their 52-week high of $139.41, with nearly all of the sell-off driven by fears over U.S.-China trade tensions, shifting tariff policies, and broader macroeconomic uncertainty.
Yet the market’s dire outlook for the company is wildly out of step with its actual operating performance. Contrary to the pessimism baked into the stock price, PDD’s top-line growth remains remarkably resilient: the firm posted a 12% year-over-year revenue increase in the fourth quarter of 2025, even amid cross-border headwinds and a muted global consumer spending environment. Temu continues to gain steady traction with shoppers worldwide, maintaining strong user engagement, expanding its global footprint, and holding its ground against rival e-commerce platforms.
While trade uncertainty remains a legitimate near-term overhang, the company has repeatedly proven its ability to navigate shifting regulatory landscapes and adapt to evolving market conditions. For patient investors, the current pullback represents a compelling entry window: even a modest stabilization in U.S.-China trade relations, or a continuation of the company’s steady revenue growth, could unlock significant upside for the stock.
The biggest draw for value-focused investors right now is the stock’s rock-bottom valuation: PDD trades at a forward P/E ratio of just 8, one of the lowest multiples among large-cap global growth stocks. That ultra-low valuation builds in an exceptional margin of safety, even if growth moderates further from its peak levels. With Temu’s expanding user base, industry-leading supply chain efficiency, and massive untapped international growth potential, the company’s long-term upside remains significantly underappreciated by Wall Street.
Amid a market fixated on short-term hype and fragile, overvalued tech stocks, Novo Nordisk and PDD Holdings stand out as rare high-quality bets. The profitable industry leaders own durable competitive moats yet trade at steep discounts, as market sentiment overstates their fundamental downside risks. Though Novo Nordisk faces fiercer GLP-1 competition and PDD deals with persistent cross-border trade and geopolitical headwinds, these hurdles are temporary and non-existential, leaving both stocks materially mispriced for patient long-term investors.
Against frothy meme stocks and pricey tech names with shaky outlooks, these two oversold growth stocks offer far stronger risk-reward dynamics. In a broadly stretched bull market with few remaining bargains, these overlooked industry leaders deliver standout value potential for disciplined investors.
